Pharmicell파미셀
005690 · KOSPI · ₩005690 · 파미셀
- Market cap
- ₩588B
- Enterprise value
- ₩598B
- P/E
- 13.6×
- P/B
- 4.1×
- Dividend yield
- 0.5%
- ROE
- 30.2%
- Net margin
- 31.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−53.7% from the high
₩8,140Today: ₩9,790 – ₩10,070₩21,150
Returns
- 1W−7.0%
- 1M−21.9%
- 3M+0.3%
- 6M−50.5%
- YTD−32.6%
- 1Y−41.2%
- Volume today
- 296,961
- 0.4× the 20-day average
- Traded today
- ₩2.9B
- Listed shares
- 60,004,014
- EPS (12 months)
- ₩721
- Earnings yield 7.4%
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 29 of 100 (50 is a normal day for this stock).
- MomentumWeak-22.2% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Pharmicell stock overview
Pharmicell (파미셀, KRX: 005690) is listed on KOSPI, in the Electronic components sector. The company is a Korean biopharmaceutical firm that developed Hearticellgram-AMI, described as the world's first stem cell therapy, for acute myocardial infarction. Its shares closed at ₩9,800 on Oct 27, 2026, up 2.08% on the day, giving it a market value of ₩588B.
Key facts
- Market cap
- ₩588B
- Sector
- Electronic components
- Latest price change
- +2.08%
- As of
- Oct 27, 2026
- Main business
- The company is a Korean biopharmaceutical firm that developed Hearticellgram-AMI, described as the world's first stem cell therapy, for acute myocardial infarction.
Quick answers about Pharmicell
- What does Pharmicell do?
- The company is a Korean biopharmaceutical firm that developed Hearticellgram-AMI, described as the world's first stem cell therapy, for acute myocardial infarction. It has two divisions: a biomedical division focused on stem cell therapy, adult stem cell storage, and cosmetics containing stem cell culture extracts, and a biochemical division producing fine chemicals such as nucleosides, PEG derivatives, eco-friendly flame retardants, electronic materials, and pharmaceutical intermediates. Its main customers are pharmaceutical, electronics, textile, and industrial chemical clients, and its main production facilities are in Seongnam and Ulsan.
- What is the market cap of Pharmicell?
- The market capitalisation of Pharmicell was ₩588B at the close on Oct 27, 2026.
- Who are the largest shareholders of Pharmicell?
- According to the latest official filings, the largest reported holders are Kim Hyun-soo (11.72%, as of Oct 8, 2026); National Pension Service (2.38%, as of Dec 31, 2025); VANGUARD TOTAL INTERNATIONAL STOCK INDEX FUND (1.33%, as of Jul 31, 2026).
- When is the next earnings report from Pharmicell?
- Korean companies rarely announce results dates in advance. Based on when Pharmicell filed the same report in past years, its next 3q results is expected between Nov 6, 2026 and Nov 13, 2026.
- Does the National Pension Service own Pharmicell?
- Yes. The National Pension Service held 2.38% of Pharmicell shares as of Dec 31, 2025.
Company profile
The company is a Korean biopharmaceutical firm that developed Hearticellgram-AMI, described as the world's first stem cell therapy, for acute myocardial infarction. It has two divisions: a biomedical division focused on stem cell therapy, adult stem cell storage, and cosmetics containing stem cell culture extracts, and a biochemical division producing fine chemicals such as nucleosides, PEG derivatives, eco-friendly flame retardants, electronic materials, and pharmaceutical intermediates. Its main customers are pharmaceutical, electronics, textile, and industrial chemical clients, and its main production facilities are in Seongnam and Ulsan.
Written by AI from the company's latest annual report.
- Korean name
- 파미셀
- Sector
- Electronic components
- Themes
- Biotech (new drugs)
- CEO
- 김현수
- Founded
- Aug 1968
- Listed
- May 1988
- Listed shares
- 60,004,014
- Fiscal year ends
- Month 12
- Website
- www.pharmicell.com
Similar companies
- Samsung Electro-Mechanics009150 · ₩90T₩1,201,000+7.42%
- Doosan000150 · ₩14T₩952,000+5.66%
- Hanwha Systems272210 · ₩12T₩63,100−0.94%
- LG Innotek011070 · ₩8.9T₩374,500+2.04%
- Isupetasys007660 · ₩6.5T₩89,000+6.59%
- Daeduck Electronics353200 · ₩6.3T₩127,700+6.68%
- Leeno Industrial058470 · ₩4.7T₩61,400+4.07%
- Simmtech222800 · ₩4.6T₩117,200+9.23%
Recent filings
See all- Major sales or supply contractOct 14, 2026
- Investor relations (IR) eventOct 12, 2026
- 5%+ holding reportOct 8, 2026
- Half-year report (Jun 2026)Aug 12, 2026
- Major sales or supply contractAug 7, 2026
Titles in Korean until English translations are added.
Also known as: Pharmicell / 파미셀 / 005690 / KRX:005690
Source: KRX statistical information